Chinese researchers have developed AiCE, an artificial intelligence-informed approach that dramatically enhances protein engineering efficiency. The method integrates structural and evolutionary constraints into existing AI models, achieving 36-90% improvements in predictive accuracy whilst eliminating the need for specialised model training.

The collaboration combines GenNext’s AutoFox protein footprinting technology with Thermo Fisher’s mass spectrometry solutions to create an integrated workflow for biotherapeutic development, offering researchers enhanced capabilities for validating AI-generated protein structural models whilst streamlining complex analytical processes.

Austrian biotech HeartBeat.bio has partnered with German AI company biotx.ai to identify and validate novel therapeutic targets for heart failure treatment. The collaboration integrates biotx.ai’s genome-wide causal mapping platform with HeartBeat.bio’s human cardiac organoid technology, aiming to accelerate precision medicine development for the 30 million patients affected globally.